Aurobindo Pharma Limited — Important, 02-07-2025: General Updates

Aurobindo Pharma’s subsidiary CuraTeQ Biologics has received European Commission approval for Dazublys™, its trastuzumab biosimilar. This marks CuraTeQ’s third EMA-approved biosimilar following Dyrupeg™ and Zefylti™, and the fourth EU biosimilar overall, including Bevqolva™ approved by the UK MHRA. The approval strengthens Aurobindo’s position in the EU biosimilars market, expanding its oncology portfolio with potential revenue growth from these high-value specialty drugs.